Food & Drug Administration (FDA) expressed safety concerns with compounded GLP-1 drugs
The key consideration is managing potential side effects rather than avoiding concurrent use altogether, and most patients tolerate both medications without significant problems when appropriate supportive measures are implemented
The good news is that these symptoms are often manageable and tend to fade over time
Food and Drug Administration (FDA) - "Saxenda (Liraglutide) Injection, for Subcutaneous Use." Accessed on April 3, 2024, at FDA - "Drug Compounding and Drug Shortages." Accessed on April 3, 2024, at Harvard T.H
Exposure to temperatures above 86F (30C) for extended periods can cause protein denaturation, where the molecular structure unfolds or aggregates, rendering the medication less effective or inactive
Can You Take a Combination of Tesamorelin and Ipamorelin